Scholarly article on topic 'Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism'

Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism Academic research paper on "Clinical medicine"

Share paper
Academic journal
PPAR Research
OECD Field of science

Academic research paper on topic "Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism"

Hindawi Publishing Corporation PPAR Research

Volume 2008, Article ID 132960, 11 pages doi:10.1155/2008/132960

Review Article

Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism

Sander Kersten

Nutrigenomics Consortium and Nutrition, Metabolism and Genomics Group, Wageningen University, P.O. Box 8129, 6700 Wageningen, EV, The Netherlands

Correspondence should be addressed to Sander Kersten, Received 22 July 2007; Accepted 3 September 2007 Recommended by Giulia Chinetti

Plasma lipoproteins are responsible for carrying triglycerides and cholesterol in the blood and ensuring their delivery to target organs. Regulation of lipoprotein metabolism takes place at numerous levels including via changes in gene transcription. An important group of transcription factors that mediates the effect of dietary fatty acids and certain drugs on plasma lipoproteins are the peroxisome proliferator activated receptors (PPARs). Three PPAR isotypes can be distinguished, all of which have a major role in regulating lipoprotein metabolism. PPARa is the molecular target for the fibrate class of drugs. Activation of PPARa in mice and humans markedly reduces hepatic triglyceride production and promotes plasma triglyceride clearance, leading to a clinically significant reduction in plasma triglyceride levels. In addition, plasma high-density lipoprotein (HDL)-cholesterol levels are increased upon PPARa activation in humans. PPARy is the molecular target for the thiazolidinedione class of drugs. Activation of PPARy in mice and human is generally associated with a modest increase in plasma HDL-cholesterol and a decrease in plasma triglycerides. The latter effect is caused by an increase in lipoprotein lipase-dependent plasma triglyceride clearance. Analogous to PPARa, activation of PPARj8/5 leads to increased plasma HDL-cholesterol and decreased plasma triglyceride levels. In this paper, a fresh perspective on the relation between PPARs and lipoprotein metabolism is presented. The emphasis is on the physiological role of PPARs and the mechanisms underlying the effect of synthetic PPAR agonists on plasma lipoprotein levels.

Copyright © 2008 Sander Kersten. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Plasma lipoproteins are responsible for carrying triglycerides and cholesterol in the blood and ensuring their delivery to target organs. Extensive research over the past few decades has demonstrated that elevated plasma levels of cholesterol-rich low-density lipoproteins (LDLs) are associated with increased risk for coronary heart disease, whereas elevated levels of high-density lipoproteins (HDLs) have a protective effect. Accordingly, raising HDL levels and especially lowering LDL levels has become the cornerstone for the nutritional and pharmacological prevention and treatment of coronary heart disease. While lowering of plasma LDL can be efficiently and adequately achieved by treatment with statins, limited pharmacological treatment options are available for efficiently raising HDL levels. Hence, the quest for effective and safe drugs that raise HDL levels and/or decrease the atherogenic properties of plasma lipoproteins continues.

A group of proteins that plays a major role in the regulation of lipoprotein metabolism and can be considered as major drug targets for correcting abnormal plasma lipoprotein levels are the nuclear receptors [1]. Nuclear receptors are ligand-activated transcription factors that alter gene transcription by direct binding to specific DNA response elements in target genes [2]. In addition, they modulate transcription by interfering with specific intracellular signaling pathways, thereby impairing transcriptional activation by other transcription factors. Nuclear receptors share a common modular structure that includes a relatively well-conserved central DNA-binding domain and a C-terminal ligand binding domain (LBD) [2]. Several nuclear receptors have been shown to be involved in the regulation ofplasma lipoprotein metabolism, including the estrogen receptors (ERs), the oxysterol receptors (LXRs), the bile acid receptor (FXR), and the fatty acid receptors (PPARs). Here, the emphasis will be on the role of PPARs.

The PPAR family includes three members encoded by distinct genes: a, ft/S, and y[3j. Since the initial discovery of the PPARa isotype in 1990 [4], an impressive amount of literature on these receptors has accumulated. PPARs mainly operate by governing the expression of specific sets of genes. Analogous to many other nuclear receptors, PPARs bind to DNA and regulate transcription as a heterodimer with the retinoid X receptor (RXR) [5]. The genomic sequence recognized by PPARs, referred to as PPAR response element or PPRE, consists of a direct repeat of the consensus hex-americ motif AGGTCA interspaced by a single nucleotide. Functional PPREs have been identified in genes involved in a variety of biological processes including lipid and glucose metabolism, detoxification, and inflammation [6]. Activation of transcription by PPARs is achieved by binding of specific ligands to the LBD, followed by recruitment of coacti-vator proteins and dissociation of corepressors. Coactivator recruitment generally leads to an increase in enzymatic activity of histone acetyltransferases, histone methyltransferases, and subsequent nucleosome remodeling, activities which are essential to initiate transcription of PPAR target genes. X-ray crystallographic analysis of the LBD of PPARs has revealed an exceptionally spacious ligand binding pocket that can be occupied by a wide variety of synthetic and natural agonists, including numerous fatty acids and fatty acid-derived eicosanoids [7, 8].

The three PPARs are distinguishable by specific tissue and developmental patterns of expression and by their activation by distinct, yet overlapping, ligands [9]. The PPARa isotype is well expressed in tissues such as liver, heart, and small intestine and regulates a variety of target genes involved in cellular lipid metabolism ranging from mitochondrial, peroxisomal, and microsomal fatty acid oxidation to fatty acid uptake and binding, lipolysis, lipogenesis, and glycerol metabolism [6]. In contrast, PPARy, which is highly expressed in brown and white adipose tissue, directs the expression of genes involved in adipocyte differentiation and fat storage. In addition, PPARy governs glucose uptake and storage [10]. Much less is known about the ubiquitously expressed PPARft/S, although recent evidence suggests an involvement in wound healing [11], fatty acid oxidation [12], and lipoprotein metabolism [13].

Here we present an overview of the literature on PPARs and lipoprotein metabolism. The emphasis is on physiological role of PPARs and the mechanisms underlying the effect of synthetic PPAR agonists on plasma lipoproteins.


The seminal evidence that placed PPARa at the center of lipoprotein metabolism was the demonstration that fibrates, which had been used clinically for many years to treat dys-lipidemia, act by binding to PPARa and induce PPARa-dependent gene transcription [4, 14]. The role of PPARa in lipoprotein metabolism could thus be extrapolated retrospectively by analyzing the reported effect of fibrates. The availability of PPARa null mice further spurred progress in elucidating PPARa function and has resulted in an extensive picture of the role of PPARa in lipoprotein metabolism [15].

Numerous clinical studies in humans have provided ample evidence that fibrates, which include clofibrate, bezafi-brate, fenofibrate, and gemfibrozil, effectively lower fasting plasma triglycerides (TG) [16-19]. The plasma TG lowering effect of fibrates can be reproduced in mice [20, 21]. Conversely, plasma TG levels are elevated in mice lacking PPARa [22]. Since in the fasted state plasma TG are carried mainly in the form of very low-density lipoproteins (VLDL), this suggests that PPARa suppresses VLDL production in liver and/or stimulates clearance of VLDL triglycerides in peripheral tissues.


Limited data are available on the effect of fibrates on production and secretion of VLDL in humans. In one study, the PPARa agonist gemfibrozil decreased production of VLDL-TG, while clofibrate had no effect [23]. In mice, PPARa has been shown to have a major impact on hepatic TG secretion. Indeed, deletion of PPARa is associated with a significant increase in VLDL-TG production in liver [24, 25]. In contrast, activation of PPARa using Wy14643 dramatically lowers VLDL-TG production (Figure 1). Furthermore, activation of PPARa suppresses TG secretion from primary rat hepatocytes [26].

VLDL is synthesized by the stepwise lipidation of the structural component apolipoprotein B through the action of microsomal triglyceride transfer protein (MTTP), resulting in the gradual formation of a mature TG-rich VLDL1 particle [27]. It may be expected that elevated hepatic TG levels increase VLDL secretion, on the one hand by targeting apolipoprotein B away from degradation toward secretion, thus increasing VLDL particle number, and on the other hand by increasing the amount of TG that becomes incorporated into VLDL, thus increasing VLDL particle size [2729]. However, a positive correlation between hepatic TG and VLDL production is not always evident, as illustrated by the lack of change in hepatic VLDL production in ob/ob mice despite massive steatosis [30]. These data feed a growing recognition that the relation between hepatic TG storage and VLDL production is dependent on where the excess TG are stored. This argument holds both at the tissue level, as only excess TG stored in the periportal area may promote VLDL formation, and at the cellular level, as TG incorporated into VLDL are likely drawn from specific intracellular lipid compartments.

Numerous studies have shown that PPARa activation lowers liver TG levels, especially in the context of a fatty liver [31-36]. Conversely, deletion of PPARa is associated with elevated hepatic TG stores, which is evident under normal fed conditions but becomes considerably more pronounced after prolonged fasting and chronic high fat feeding [22, 3740]. The potent effect of PPARa activation and deletion on hepatic TG levels is illustrated in Figure 2. Remarkably, treatment of wildtype but not PPARa null mice with Wy14643 for 10 days can completely prevent the fasting-induced increase in hepatic TG, most likely by stimulating fatty acid oxidation. Indeed, probably the best understood property of PPARa is its ability to stimulate fatty acid oxidation by upregulating


90 Minutes

O Wy14643-tyloxapol • Wy14643-saline

□ Vehicle-tyloxapol ■ Vehicle-saline

'S 0.08

g 0.06

<3 0.04



Figure 1: The PPARa agonist Wy14643 dramatically lowers VLDL production in a mouse model of hypertriglyceridemia. Male Angptl4-transgenic mice (n = 7 per group) were given vehicle or Wy14643 for 10 days (0.1% mixed in their food). After a 24-hour fast, the LPL-inhibitor tyloxapol (Triton WR1339, 500mg/kg bodyweight as 15% solution in saline) or saline were injected intraorbitally. (a) Plasma triglyceride concentration was measured every 30 minutes to determine the VLDL production rate. (b) Mean rate of increase of plasma TG concentration in mice that received tyloxapol. Differences were evaluated by Student's t-test (***P < .001). Error bars represent SEM.

almost every single gene within the mitochondrial, peroxisomal, and microsomal fatty acid oxidation pathway, including carnitine palmitoyl transferase 1 and 2, acyl-CoA oxidase, acyl-CoA dehydrogenases, and numerous others [6]. Many of these genes have been identified as direct PPARa targets characterized by the presence of a functional PPRE. Accordingly, the most plausible explanation for the hepatic TG lowering effect of PPARa activation is that by promoting fatty acid oxidation, PPARa shifts fatty acids away from esterifica-tion and storage. While its effect on fatty acid oxidation likely accounts for the major share of its antisteatotic action, regulation of other genes and pathways by PPARa may contribute to some extent as well.

Suppression of VLDL production by PPARa agonists is generally attributed to lowering of hepatic TG stores, despite uncertainties surrounding the relationship between hepatic TG storage and VLDL production. In addition to its role in fatty acid catabolism, PPARa impacts on multiple aspects of intracellular lipid trafficking and metabolism, some of which may oppose hepatic TG lowering, including induction of genes involved in fatty acid synthesis and fatty acid elongation/desaturation [41-44]. Furthermore, expression of MTTP, which is involved in the lipidation of apoB100 to form a nascent VLDL particle, has recently been shown to be increased by PPARa [21]. Upregulation of MTTP may promote apoB100 secretion, which together with a decreased TG availability may favor the targeting of apoB100 to IDL and LDL rather than VLDL [21]. Interestingly, a recent study points to adipose differentiation-related protein (ADRP), which is a direct target gene of PPARa [45], as a potential mediator of the effect of PPARa on VLDL production. Using cultured cells it was shown that an increase in ADRP pre-

vents the formation of VLDL by diverting fatty acids from the VLDL assembly pathway into cytosolic lipid droplets [46]. It can be expected that as the process of VLDL assembly and secretion becomes better understood and the role of PPARa in this process is further clarified, the general view on the mechanism underlying the effect of PPARa on hepatic VLDL secretion may change.


Several studies have examined the impact of PPARa on clearance of TG-rich lipoproteins in humans, all of which show increased clearance after treatment with PPARa agonists [23, 47-49]. Clearance of VLDL-TG from plasma is mediated by the enzyme lipoprotein lipase (LPL) which thus has a critical role in determining plasma TG concentrations. LPL is synthesized mainly by adipocytes and myocytes, and after translocation to capillary endothelial cells it is anchored into the vessel wall via heparin-sulphate proteoglycans. Treatment of human subjects with PPARa agonists is associated with a significant increase in postheparin total LPL activity, suggesting that stimulation of plasma TG clearance by PPARa agonists can be attributed to enhanced LPL activity [49-51].

Theoretically, changes in LPL activity can be achieved by altering the production of LPL itself, or by altering the production of proteins that assist with LPL function or modulate its enzymatic activity. The latter group includes apolipopro-teins such as APOC3, APOC2, and APOA5, as well as angiopoietin-like proteins 3 and 4. While it is clear that expression of LPL is upregulated by PPARa in liver [52], no evidence is available indicating a role for PPARa in governing LPL expression in heart and skeletal muscle. According

Figure 2: The PPARa agonist Wy14643 prevents the fasting-induced increase in liver TG levels. Male wild-type and PPARa null mice (n = 5 per group) were given vehicle or Wy14643 for 10 days (0.1% mixed in their food). After a 24-hour fast, livers were dissected and stained histochemically using hematoxylin/eosin (a) or oil Red O (b). Representative livers sections are shown. Differences visualized by histochemistry were perfectly confirmed by quantitative measurement of hepatic TG levels.

to our unpublished microarray data, neither PPARa deletion nor 5-day treatment with Wy14643 had any influence on LPL mRNA expression in mouse heart. It thus appears that rather than by regulating expression of LPL itself, PPARa agonists stimulate plasma TG clearance by altering the hepatic expression of inhibitors or activators of LPL activity. In both mouse and human, hepatic mRNA expression and plasma levels of APOC3, which inhibits LPL activity, are lowered by PPARa agonists [53-56]. Several mechanism have been put forward to explain downregulation of APOC3 expression by PPARa, involving the transcription factors Reverba, HNF4a, or FOXO1 [57-60]. In contrast to APOC3, PPARa agonists increase hepatic expression and plasma levels of APOA5, an activator of LPL [61]. A functional PPAR responsive element has been identified in the promoter of the human APOA5 gene, classifying APOA5 as a direct PPARa target gene [62, 63].

It can be hypothesized that the stimulatory effect of PPARa on clearance of TG-rich lipoproteins may be counterbalanced by PPARa-dependent upregulation of the LPL inhibitor Angptl4 [64, 65]. Plasma levels of Angptl4 are in-

creased by fenofibrate treatment [66]. Data obtained from various transgenic mouse models and from human genetic studies indicate that Angptl4 inhibits the clearance of TG-rich lipoproteins, likely by stimulating the conversion of catalytically active dimeric LPL to catalytically inactive monomeric LPL [67-72]. It can be speculated that upregulation of Angptl4 may explain the inhibitory effect of PPARa agonists on LPL activity in macrophages, adipose tissue, and cardiomyocytes [73-76].


In addition to their plasma TG-lowering effect, fibrates are used clinically for their ability to raise plasma HDL-cholesterol (HDLc) levels. A recent meta-analysis of 53 clinical trials indicates that on average, fibrates elevate plasma HDLc levels by about 10%, which translates into a 25% reduction in risk for major coronary events [77]. Remarkably, this effect is not observed in rodents, which seriously complicates study of the molecular mechanisms underlying the effect of PPARa agonists on HDL. In mice, plasma

total cholesterol and HDLc levels are reduced by treatment with synthetic PPARa agonists [78], whereas levels are increased in mice lacking PPARa [20]. The differential effects of PPARa on plasma HDL between mouse and human is likely due to species-specific regulation of apolipoprotein A-I (APOA1), the core apolipoprotein of HDL. Whereas PPARa activation increases plasma levels and hepatic mRNA expression of APOA1 in human, as supported by studies using human APOA1 transgenic mice and human hepatocytes [79], the opposite effect is observed in rodents [78]. The lack of upregulation of APOA1 gene expression by PPARa in rat was attributed to 3 nucleotide differences between the rat and the human APOA1 promoter A site, rendering a positive PPAR-response element in the human APOA1 promoter nonfunctional in rats [80]. In addition to APOA1, plasma levels and hepatic mRNA expression of APOA2, another major apolipoprotein component of HDL, are also increased by fibrates in humans [51, 81]. In contrast, in rodents both a reduction and induction of APOA2 expression after treatment with fibrates have been observed [20, 78].

In recent years, our knowledge regarding the mechanisms and location of HDL formation has improved considerably. Recent evidence suggests that the intestine and liver are responsible for the major share of HDL synthesis [82, 83]. It is generally believed that HDL is formed by lipidation of lipid poor APOA1 mediated by the cholesterol efflux transporter ABCA1. The importance of ABCA1 in HDL synthesis is illustrated by the almost complete absence of HDL from plasma of patients with a dysfunctional ABCA1 gene [84]. This metabolic abnormality is reproduced in mice that lack ABCA1 [85, 86]. Importantly, the expression of ABCA1 is increased by PPARa in intestine and macrophages [87, 88]. No PPRE has yet been identified in the human or mouse ABCA1 gene, suggesting that ABCA1 may not be a direct PPARa target. Instead, upregulation of ABCA1 mRNA by PPARa agonists in macrophages likely occurs via PPARa-dependent upregulation of LXR, which is a transcriptional activator of ABCA1 [88, 89]. Whether the same mechanism operates in intestine remains unclear.

Recently, ABCG1 was identified as the transporter responsible for cellular efflux of cholesterol towards mature HDL [90]. So far no evidence is available that suggests regulation of ABCG1 by PPARs.

Several proteins are involved in HDL remodeling including lecithin cholesterol acyltransferase (LCAT), phospholipid transfer protein (PLTP), and cholesteryl ester transfer protein (CETP). In mice, fibrates decrease plasma LCAT activity and hepatic LCAT mRNA expression [91]. Hepatic expression and plasma activity of PLTP, which increases HDL particle size by catalyzing the transfer of phospholipids from VLDL/IDL to HDL, are increased by PPARa in wild-type but not PPARa null mice. Accordingly, upregulation of PLTP may account for the observed increase in HDL particle size in mice treated with fibrates [92]. Since CETP is absent from mice, the role of PPARa in the regulation of CETP activity has largely remained elusive. Interestingly, in a recent study using hCETP-transgenic mice on an apoE3 Leiden background, it was found that fenofibrate markedly reduced CETP activity in parallel with an increase in plasma HDLc

levels [93]. These data imply that fibrates reduce CETP activity in humans, suggesting that the effect offibrates on plasma HDL levels in humans may be partially achieved by suppressing CETP activity. In addition, it can be speculated that as PPARa activation decreases plasma VLDL levels, the acceptor pool for the CETP-catalyzed exchange of cholesterol-esters with HDL will be diminished, resulting in increased HDL size.

HDL cholesterol can also be cleared by the SCARB1-mediated selective removal of cholesterol from the HDL particle, or by endocytic uptake and degradation of the whole particle, called holoparticle HDL uptake. A possible mechanism by which fibrates may impair HDL clearance is by downregulating hepatic SCARB1 gene expression in a PPARa dependent manner [94].


While the role of PPARa in the regulation of lipoprotein metabolism is relatively well characterized, much less is known about PPARfi/8. Initial studies in mice showed that selective PPAR3/8 agonists raise plasma HDLc levels [13,95]. The HDLc-raising effect is also evident in rhesus monkeys

[96], and, according to a recent report, in human subjects

[97]. In monkey and human, but seemingly not in mice, PPARfi/8 agonists decrease plasma TG levels as well. The mechanism behind the HDLc-raising effect of PPARfi/8 agonists remains obscure, although a role for ABCA1, which is upregulated by PPARfi/8, has been proposed [96].

In line with the plasma TG-lowering effect of PPAR^/8 agonists observed in primates, plasma TG levels are elevated in PPAR^/8 null mice [98]. In contrast, plasma total cholesterol and HDLc remain unchanged. It was proposed that the elevated plasma TG levels in PPAR^/8 null mice are caused by a combination of increased VLDL production and decreased plasma TG clearance, as evidenced by a decrease in postheparin LPL activity and increased hepatic expression of LPL inhibitors Angptl3 and 4. Overall, insight into the molecular mechanisms that may underlie the observed changes in plasma lipoproteins is lacking, which is partly due to the fact that very few PPAR^/8 specific or selective target genes are known. Since PPARa agonists also increase plasma HDLc levels, it might be hypothesized that PPAR^/8 agonists might act via common molecular targets. However, at least in mice, PPARa and PPAR^/8 agonists display divergent effect on plasma TG levels, suggesting a different mode of action.


Synthetic PPAR) agonists are prescribed for their ability to promote insulin sensitivity and lower plasma glucose levels in patients suffering from type 2 diabetes mellitus (T2DM). On top of an insulin-sensitizing action, numerous studies in mice and humans have shown that use of PPAR) agonists leads to a reduction in fasting and postprandial plasma TG levels [99-103]. Some variability in the plasma TG lowering effect is observed between different PPAR) agonists, and in mice between various disease models. Indeed, no effect of PPAR) agonists on plasma TG is observed in the two mouse

models most commonly used for atherosclerosis research, which are the LDL receptor knock-out and apoE knock-out mice [104]. In humans rosiglitazone seems to specifically lower postprandial but not fasting TG levels [105, 106]. Evidence has been provided that the plasma TG lowering effect of PPARy agonists maybe connected to their insulin sensitizing action by suppressing adipose tissue lipolysis and plasma FFA levels, which is expected to lead to decreased hepatic VLDL-TG production [106]. However, no relationship exists between the insulin-sensitizing potency of PPARy agonists and plasma TG lowering [107]. Furthermore, in a recent study, treatment of type 2 diabetic subjects with piogli-tazone did not result in any change in hepatic VLDL-TG production [108]. Thus, whereas PPARa agonist lowers plasma TG by a combination of suppressing hepatic VLDL production and stimulating plasma TG clearance, PPARy agonists seem to lower plasma TG exclusively by enhancing plasma TG clearance [100, 108].

The stimulatory effect of PPARy agonists on plasma TG clearance is achieved by upregulating LPL expression and activity in adipose tissue [52,100,106,109,110], which is associated with an increase in postheparin plasma LPL mass/total activity [101, 102]. As a consequence, LPL-mediated lipoly-sis and the fractional clearance rate ofVLDL-TG are elevated [108]. Besides directly regulating LPL production, PPARy agonists may influence LPL-mediated lipolysis by decreasing plasma levels of APOC3, a potent inhibitor of LPL [108].

Interestingly, in rats induction of LPL activity and gene expression by PPARy agonist was observed in inguinal but not retroperitoneal adipose tissue [111]. This type of adipose depot-specific regulation of LPL by PPARy likely accounts for the redistribution of stored fat from visceral towards subcutaneous adipose tissue upon treatment with PPARy agonists [112]. Also, no induction of LPL expression by PPARy was observed in murine skeletal muscle [113].

In contrast to what is observed in vivo, PPARy agonists decrease LPL activity in primary rat and mouse 3T3 adipocytes [100, 114]. It can be hypothesized that the inhibition of LPL activity may be mediated by upregulation of Angptl4, similar to what was discussed for the suppression of LPL activity in various cell types after treatment with PPARa agonist. In light of the recent finding that rosiglita-zone raises plasma Angptl4 levels in human subjects [115], and that Angptl4 increases abundance of monomeric LPL in preheparin plasma (our unpublished data), it can be speculated that upregulation of Angptl4 may also account for the observed increase in plasma preheparin LPL levels in subjects treated with pioglitazone [ 108].

Use of gene targeting to study of the role of PPARy in regulation of lipoprotein metabolism has been complicated by the lethality of PPARy null mice. However, mice with a specific ablation of the PPARy2 isoform are viable and, opposite to the effect of PPARy agonists, show elevated plasma TG levels, especially on a leptin-deficient background [116]. A similar elevation of plasma TG was observed in mice in which PPARy was specifically deleted in adipose tissue [117].

Apart from LPL, very few PPARy target genes that impact on TG-rich lipoproteins are known. It has been shown that

LDL-receptor-related protein 1 (LRP-1), which is involved in clearance of cholesteryl-esters from chylomicron remnants and possibly HDL, is a direct target gene of PPARy in human adipocytes [118]. These data suggest that upregulation of LRP-1 may contribute to the stimulatory effect of PPARy agonists on clearance of TG-rich lipoproteins.


Although PPARy agonists are best known for their ability to lower plasma glucose and TG levels, depending on the type of PPARy agonist and the type of animal species/model, plasma levels of cholesterol and specific lipoprotein subclasses may be altered as well [104, 119]. Recently, the results of two large clinical trials involving either rosiglitazone or piogli-tazone were reported. In the ADOPT trial, 4360 subjects recently diagnosed with T2DM were randomly assigned to treatment with metformin, glyburide, or rosiglitazone. After 4 years, plasma HDLc levels were modestly higher in the rosiglitazone-treated patients [120]. In the proactive trial, 5238 patients with type 2 diabetes received either piogli-tazone or placebo. Again, a significant increase in plasma HDLc levels was observed in the patients treated with piogli-tazone [121]. The small but reproducible increase in plasma HDLc upon treatment with PPARy agonists was substantiated in a meta-analysis summarizing the effects of thiazo-lidinediones from a large number of randomized controlled trails [122]. In addition, treatment with PPARy agonists is associated with an increase in LDL size [101, 103, 119]. It has been reported that the relative efficacy of pioglitazone towards ameliorating plasma lipid levels is more favorable compared to rosiglitazone [119].

Presently, the mechanism(s) behind the HDLc raising effect of PPARy agonists remains elusive. Possibly, PPARy agonists may carry minor agonist activity towards PPARa. However, in contrast to PPARa agonists, PPARy agonists do not appear to have any effect of APOA1 and APOA2 syntheses [100, 108]. The observation that plasma HDLc levels do not respond to PPARy agonist treatment in rodents complicates study of the underlying mechanisms [100]. It is conceivable that the modest increase in HDLc following PPARy agonist treatment is due to reduced CETP-mediated exchange of VLDL TGs for HDL cholesterol, concomitant with a drop in VLDL-TG levels. Finally, PPARy has been shown to up-regulate expression of ABCA1 in macrophages [88, 123]. As ABCA1 is required for the flux of cholesterol from cells onto APOA1 to form nascent HDL, upregulation of ABCA1 by PPARy may contribute to the HDLc-raising effect of PPARy. However, it still needs to be demonstrated that expression of ABCA1 is under control of PPARy in tissues responsible for the major share of HDL synthesis, which are intestine and liver.


PPARs have a major impact on levels of lipoproteins in plasma by governing the expression of numerous genes involved in the synthesis, remodeling, and clearance of plasma lipids and lipoproteins. The changes in plasma lipoprotein

levels associated with treatment with PPAR agonists, characterized by decreased plasma TG levels, increased HDLc, and an increase in LDL size, are expected to decrease the risk for cardiovascular disease. In recent years, several new proteins that play a role in lipoprotein metabolism have been identified. In addition, the functional characterization of other proteins involved in lipoprotein metabolism has advanced significantly. As progress is made in PPAR-dependent gene regulation, especially in human, our insight into the molecular mechanisms underlying the effects of PPARs on plasma lipoproteins will further continue to improve.


[1] A. Chawla, J. J. Repa, R. M. Evans, and D. J. Mangelsdorf, "Nuclear receptors and lipid physiology: opening the X-files," Science, vol. 294, no. 5548, pp. 1866-1870, 2001.

[2] A. Aranda and A. Pascual, "Nuclear hormone receptors and gene expression," Physiological Reviews, vol. 81, no. 3, pp. 1269-1304, 2001.

[3] S. Kersten, B. Desvergne, and W. Wahli, "Roles of PPARS in health and disease," Nature, vol. 405, no. 6785, pp. 421-424, 2000.

[4] I. Issemann and S. Green, "Activation of a member of the steroid hormone receptor superfamily by peroxisome prolif-erators," Nature, vol. 347, no. 6294, pp. 645-650, 1990.

[5] B. Desvergne and W. Wahli, "Peroxisome proliferator-activated receptors: nuclear control of metabolism," Endocrine Reviews, vol. 20, no. 5, pp. 649-688, 1999.

[6] S. Mandard, M. Muller, and S. Kersten, "Peroxisome proliferator-activated receptor a target genes," Cellular and Molecular Life Sciences, vol. 61, no. 4, pp. 393-416, 2004.

[7] R. T. Nolte, G. B. Wisely, S. Westin, et al., "Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-y," Nature, vol. 395, no. 6698, pp. 137-143,

[8] H. E. Xu, M. H. Lambert, V. G. Montana, et al., "Molecular recognition of fatty acids by peroxisome proliferator-activated receptors," Molecular Cell, vol. 3, no. 3, pp. 397-403,

[9] O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, "Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-a, -8, and -y in the adult rat," Endocrinology, vol. 137, no. 1, pp. 354-366, 1996.

[10] C. Knouff and J. Auwerx, "Peroxisome proliferator-activated receptor-y calls for activation in moderation: lessons from genetics and pharmacology," Endocrine Reviews, vol. 25, no. 6, pp. 899-918, 2004.

[11] L. Michalik, B. Desvergne, N. S. Tan, et al., "Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)a and PPARjS mutant mice," Journal of Cell Biology, vol. 154, no. 4, pp. 799-814, 2001.

[12] T. Tanaka, J. Yamamoto, S. Iwasaki, et al., "Activation of peroxisome proliferator-activated receptor S induces fatty acid j8-oxidation in skeletal muscle and attenuates metabolic syndrome," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924-15929, 2003.

[13] M. D. Leibowitz, C. Fievet, N. Hennuyer, et al., "Activation of PPARS alters lipid metabolism in db/db mice," FEBS Letters, vol. 473, no. 3, pp. 333-336, 2000.

[14] M. Gottlicher, E. Widmark, Q. Li, and J. Gustafsson, "Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4653-4657, 1992.

[15] S. S. Lee, T. Pineau, J. Drago, et al., "Targeted disruption of the a isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators," Molecular and Cellular Biology, vol. 15, no. 6, pp. 3012-3022, 1995.

[16] M. H. Frick, O. Elo, K. Haapa, et al., "Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease," The New England Journal of Medicine, vol. 317, no. 20, pp. 1237-1245, 1987.

[17] H. B. Rubins, S. J. Robins, D. Collins, et al., "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol," The New England Journal of Medicine, vol. 341, no. 6, pp. 410-418, 1999.

[18] "Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study," Circulation, vol. 102, no. 1, pp. 21-27, 2000.

[19] "Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study," The Lancet, vol. 357, no. 9260, pp. 905-910, 2001.

[20] J. M. Peters, N. Hennuyer, B. Staels, et al., "Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor a-deficient mice," Journal of Biological Chemistry, vol. 272, no. 43, pp. 27307-27312, 1997.

[21] C. Ameen, U. Edvardsson, A. Ljungberg, et al., "Activation of peroxisome proliferator-activated receptor a increases the expression and activity of microsomal triglyceride transfer protein in the liver," Journal of Biological Chemistry, vol. 280, no. 2, pp. 1224-1229, 2005.

[22] P. Costet, C. Legendre, J. More, A. Edgar, P. Galtier, and T. Pineau, "Peroxisome proliferator-activated receptor a-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis," Journal of Biological Chemistry, vol. 273, no. 45, pp. 29577-29585, 1998.

[23] Y. A. Kesaniemi and S. M. Grundy, "Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man," Journal of the American Medical Association, vol. 251, no. 17, pp. 2241-2246, 1984.

[24] K. Tordjman, C. Bernal-Mizrachi, L. Zemany, et al., "PPARa deficiency reduces insulin resistance and atherosclerosis in apoE-null mice," Journal of Clinical Investigation, vol. 107, no. 8, pp. 1025-1034, 2001.

[25] D. Linden, M. Alsterholm, H. Wennbo, and J. Oscarsson, "PPARa deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins," Journal of Lipid Research, vol. 42, no. 11, pp. 1831-1840,2001.

[26] D. Linden, K. Lindberg, J. Oscarsson, et al., "Influence of peroxisome proliferator-activated receptor a agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48," Journal of Biological Chemistry, vol. 277, no. 25, pp. 23044-23053, 2002.

[27] M. Adiels, S.-O. Olofsson, M.-R. Taskinen, and J. Boren, "Diabetic dyslipidaemia," Current Opinion in Lipidology, vol. 17, no. 3, pp. 238-246, 2006.

[28] E. A. Fisher and H. N. Ginsberg, "Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins," Journal of Biological Chemistry, vol. 277, no. 20, pp. 17377-17380, 2002.

[29] M. Adiels, M.-R. Taskinen, C. Packard, et al., "Overproduction of large VLDL particles is driven by increased liver fat content in man," Diabetologia, vol. 49, no. 4, pp. 755-765, 2006.

[30] C. H. Wiegman, R. H. J. Bandsma, M. Ouwens, et al., "Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin," Diabetes, vol. 52, no. 5, pp. 10811089,2003.

[31] M. Sekiya, N. Yahagi, T. Matsuzaka, et al., "Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression," Hepatology, vol. 38, no. 6, pp. 15291539,2003.

[32] G. Svegliati-Baroni, C. Candelaresi, S. Saccomanno, et al., "A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-a and n-3 polyunsaturated fatty acid treatment on liver injury," American Journal ofPathology, vol. 169, no. 3, pp. 846-860, 2006.

[33] M. M. Haluzik, Z. Lacinova, M. Dolinkova, et al., "Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-a agonist treatment is accompanied by paradoxical increase of circulating resistin levels," Endocrinology, vol. 147, no. 9, pp. 4517-4524, 2006.

[34] T. Nagasawa, Y. Inada, S. Nakano, et al., "Effects of bezafi-brate, PPAR pan-agonist, and GW501516, PPAR5 agonist, on development of steatohepatitis in mice fed a methionine-and choline-deficient diet," European Journal of Pharmacology, vol. 536, no. 1-2, pp. 182-191, 2006.

[35] Y. Harano, K. Yasui, T. Toyama, et al., "Fenofibrate, a peroxisome proliferator-activated receptor a agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver," Liver International, vol. 26, no. 5, pp. 613-620, 2006.

[36] P. G. P. Martin, H. Guillou, F. Lasserre, et al., "Novel aspects of PPARa-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study," Hepa-tology, vol. 45, no. 3, pp. 767-777, 2007.

[37] S. Kersten, J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne, and W. Wahli, "Peroxisome proliferator-activated receptor a mediates the adaptive response to fasting," Journal of Clinical Investigation, vol. 103, no. 11, pp. 1489-1498, 1999.

[38] T. C. Leone, C. J. Weinheimer, and D. P. Kelly, "A critical role for the peroxisome proliferator-activated receptor a (PPARa) in the cellular fasting response: the PPARa-null mouse as a model of fatty acid oxidation disorders," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7473-7478, 1999.

[39] T. Hashimoto, W. S. Cook, C. Qi, A. V. Yeldandi, J. K. Reddy, and M. S. Rao, "Defect in peroxisome proliferator-activated receptor a-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting," Journal of Biological Chemistry, vol. 275, no. 37, pp. 2891828928, 2000.

[40] R. Stienstra, S. Mandard, D. Patsouris, C. Maass, S. Kersten, and M. Müller, "Peroxisome proliferator-activated receptor a protects against obesity-induced hepatic inflammation," Endocrinology, vol. 148, no. 6, pp. 2753-2763, 2007.

[41] B. L. Knight, A. Hebbachi, D. Hauton, et al., "A role for PPARa in the control of SREBP activity and lipid synthesis in the liver," Biochemical Journal, vol. 389, no. 2, pp. 413-421, 2005.

[42] T. Matsuzaka, H. Shimano, N. Yahagi, et al., "Dual regulation of mouse 55- and 56-desaturase gene expression by SREBP-1 and PPARa," Journal of Lipid Research, vol. 43, no. 1, pp. 107-114, 2002.

[43] C. W. Miller and J. M. Ntambi, "Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression," Proceedings of the National Academy of Sciences of the United States ofAmerica, vol. 93, no. 18, pp. 9443-9448, 1996.

[44] I. J. Waterman and V. A. Zammit, "Differential effects of fenofibrate or simvastatin treatment of rats on hepatic mi-crosomal overt and latent diacylglycerol acyltransferase activities," Diabetes, vol. 51, no. 6, pp. 1708-1713, 2002.

[45] P. Targett-Adams, M. J. McElwee, E. Ehrenborg, M. C. Gustafsson, C. N. Palmer, and J. McLauchlan, "A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein," Biochimica et Biophysica Acta, vol. 1728, no. 1-2, pp. 95-104, 2005.

[46] B. Magnusson, L. Asp, P. Bostrom, et al., "Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1566-1571, 2006.

[47] A. C. Sposito, R. C. Maranhao, C. G. C. Vinagre, R. D. Santos, and J. A. F. Ramires, "Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease," Atherosclerosis, vol. 154, no. 2, pp. 455-461,2001.

[48] R. D. Santos, L. I. Ventura, A. C. Sposito, R. Schreiber, J. A. F. Ramires, and R. C. Maranhao, "The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia," Cardiovascular Research, vol. 49, no. 2, pp. 456-465, 2001.

[49] I. E. Simo, J. A. Yakichuk, and T. C. Ooi, "Effect of gemfi-brozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome," Atherosclerosis, vol. 100, no. 1, pp. 55-64, 1993.

[50] H. S. Simpson, C. M. Williamson, T. Olivecrona, et al., "Postprandial lipemia, fenofibrate and coronary artery disease," Atherosclerosis, vol. 85, no. 2-3, pp. 193-202, 1990.

[51] J.-P. Desager, Y. Horsmans, C. Vandenplas, and C. Har-vengt, "Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days," Atherosclerosis, vol. 124, supplement 1, pp. S65-S73, 1996.

[52] K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre, et al., "PPARa and PPARy activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene," The EMBO Journal, vol. 15, no. 19, pp. 5336-5348, 1996.

[53] B. Staels, N. Vu-Dac, V. A. Kosykh, et al., "Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates," Journal of Clinical Investigation, vol. 95, no. 2, pp. 705-712, 1995.

[54] J.-M. Bard, H.-J. Parra, R. Camare, et al., "A multicenter comparison of the effects of simvastatin and fenofibrate therapy

in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition," Metabolism, vol. 41, no. 5, pp. 498-503, 1992.

[55] A. Minnich, N. Tian, L. Byan, and G. Bilder, "A potent PPARa agonist stimulates mitochondrial fatty acid ß-oxidation in liver and skeletal muscle," American Journal of Physiology, vol. 280, no. 2, pp. E270-E279, 2001.

[56] I. Lemieux, H. Salomon, and J.-P. Després, "Contribution of apo CIII reduction to the greater effect of 12-week mi-cronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients," Annals of Medicine, vol. 35, no. 6, pp. 442-448, 2003.

[57] E. Raspe, H. Duez, A. Mansen, et al., "Identification of Reverba as a physiological repressor of apoC-III gene transcription," Journal of Lipid Research, vol. 43, no. 12, pp. 21722179,2002.

[58] P. Gervois, S. Chopin-Delannoy, A. Fadel, et al., "Fibrates increase human Rev-erba expression in liver via a novel peroxisome proliferator-activated receptor response element," Molecular Endocrinology, vol. 13, no. 3, pp. 400-409, 1999.

[59] R. Hertz, J. Bishara-Shieban, and J. Bar-Tana, "Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III," Journal of Biological Chemistry, vol. 270, no. 22, pp. 13470-13475, 1995.

[60] S. Qu, D. Su, J. Altomonte, et al., "PPARa mediates the hypolipidemic action of fibrates by antagonizing FoxO1," American Journal of Physiology, vol. 292, no. 2, pp. E421-E434, 2007.

[61] A. E. Schultze, W. E. Alborn, R. K. Newton, and R. J. Konrad, "Administration of a PPARa agonist increases serum apoli-poprotein A-V levels and the apolipoprotein A-V/apolipo-protein C-III ratio," Journal of Lipid Research, vol. 46, no. 8, pp. 1591-1595, 2005.

[62] X. Prieur, H. Coste, and J. C. Rodriguez, "The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-a and contains a novel farnesoid X-activated receptor response element," Journal of Biological Chemistry, vol. 278, no. 28, pp. 25468-25480, 2003.

[63] N. Vu-Dac, P. Gervois, H. Jakel, et al., "Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor a activators," Journal of Biological Chemistry, vol. 278, no. 20, pp. 17982-17985, 2003.

[64] S. Kersten, S. Mandard, N. S. Tan, et al., "Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene," Journal ofBiolog-ical Chemistry, vol. 275, no. 37, pp. 28488-28493, 2000.

[65] K. Yoshida, T. Shimizugawa, M. Ono, and H. Furukawa, "Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase," Journal of Lipid Research, vol. 43, no. 11, pp. 1770-1772,2002.

[66] S. Mandard, F. Zandbergen, N. S. Tan, et al., "The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment," Journal of Biological Chemistry, vol. 279, no. 33, pp. 34411-34420, 2004.

[67] S. Mandard, F. Zandbergen, E. van Straten, et al., "The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity," Journal of Biological Chemistry, vol. 281, no. 2, pp. 934-944, 2006.

[68] A. Köster, Y. B. Chao, M. Mosior, et al., "Transgenic angiopoietin-like (ANGPTL)4 overexpression and targeted disruption of ANGPTL4 and ANGPTL3: regulation of triglyceride metabolism," Endocrinology, vol. 146, no. 11, pp. 4943-4950, 2005.

[69] X. Yu, S. C. Burgess, H. Ge, et al., "Inhibition of cardiac lipoprotein utilization by transgenic overexpression of ANGPTL4 in the heart," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 5, pp. 1767-1772, 2005.

[70] U. Desai, E.-C. Lee, K. Chung, et al., "Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 28, pp. 11766-11771,2007.

[71] S. Romeo, L. A. Pennacchio, Y. Fu, et al., "Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL," Nature Genetics, vol. 39, no. 4, pp. 513-516, 2007.

[72] V. Sukonina, A. Lookene, T. Olivecrona, and G. Olivecrona, "Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17450-17455, 2006.

[73] J. M. Odonkor and M. P. Rogers, "Effects of ethyl-CPIB (clofi-brate) on tissue lipoprotein lipase and plasma post-heparin lipolytic activity in rats," Biochemical Pharmacology, vol. 33, no. 8, pp. 1337-1341, 1984.

[74] A. V. M. Ferreira, G. G. Parreira, A. Green, and L. M. Botion, "Effects of fenofibrate on lipid metabolism in adipose tissue of rats," Metabolism, vol. 55, no. 6, pp. 731-735, 2006.

[75] F. G. Gbaguidi, G. Chinetti, D. Milosavljevic, et al., "Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages," FEBS Letters, vol. 512, no. 1-3, pp. 85-90, 2002.

[76] R. Carroll and D. L. Severson, "Peroxisome proliferator-activated receptor-a ligands inhibit cardiac lipoprotein lipase activity," American Journal of Physiology, vol. 281, no. 2, pp. H888-H894, 2001.

[77] R. S. Birjmohun, B. A. Hutten, J. J. P. Kastelein, and E. S. G. Stroes, "Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials," Journal of the American College of Cardiology, vol. 45, no. 2, pp. 185-197, 2005.

[78] B. Staels, A. van Tol, T. Andreu, and J. Auwerx, "Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat," Arteriosclerosis and Thrombosis, vol. 12, no. 3, pp. 286-294, 1992.

[79] L. Berthou, N. Duverger, F. Emmanuel, et al., "Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice," Journal of Clinical Investigation, vol. 97, no. 11, pp. 2408-2416, 1996.

[80] N. Vu-Dac, S. Chopin-Delannoy, P. Gervois, et al., "The nuclear receptors peroxisome proliferator-activated receptor a and Rev-erba mediate the species-specific regulation of apolipoprotein A-I expression by fibrates," Journal of Biological Chemistry, vol. 273, no. 40, pp. 25713-25720, 1998.

[81] N. Vu-Dac, K. Schoonjans, V. Kosykh, et al., "Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor," Journal ofClinical Investigation, vol. 96, no. 2, pp. 741-750, 1995.

[82] J. M. Timmins, J.-Y. Lee, E. Boudyguina, et al., "Targeted inactivation of hepatic ABCA1 causes profound hypoal-phalipoproteinemia and kidney hypercatabolism of apoA-I," Journal of Clinical Investigation, vol. 115, no. 5, pp. 1333— 1342,2005.

[83] L. R. Brunham, J. K. Kruit, J. Iqbal, et al., "Intestinal ABCA1 directly contributes to HDL biogenesis in vivo," Journal of Clinical Investigation, vol. 116, no. 4, pp. 1052-1062, 2006.

[84] L. R. Brunham, R. R. Singaraja, and M. R. Hayden, "Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis," Annual Review of Nutrition, vol. 26, pp. 105-129, 2006.

[85] J. McNeish, R. J. Aiello, D. Guyot, et al., "High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 8, pp. 42454250, 2000.

[86] E. Orso, C. Broccardo, W. E. Kaminski, et al., "Transport of lipids from Golgi to plasma membrane is defective in tangier disease patients and ABC1-deficient mice," Nature Genetics, vol. 24, no. 2, pp. 192-196, 2000.

[87] B. L. Knight, D. D. Patel, S. M. Humphreys, D. Wiggins, and G. F. Gibbons, "Inhibition of cholesterol absorption associated with a PPARa -dependent increase in ABC binding cassette transporter A1 in mice," Journal of Lipid Research, vol. 44, no. 11, pp. 2049-2058, 2003.

[88] G. Chinetti, S. Lestavel, V. Bocher, et al., "PPAR-a and PPAR-y activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway," Nature Medicine, vol. 7, no. 1, pp. 53-58, 2001.

[89] J. J. Repa, S. D. Turley, J.-M. A. Lobaccaro, et al., "Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers," Science, vol. 289, no. 5484, pp. 15241529,2000.

[90] N. Wang, D. Lan, W. Chen, F. Matsuura, and A. R. Tall, "ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9774-9779, 2004.

[91] B. Staels, A. van Tol, G. Skretting, and J. Auwerx, "Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates," Journal of Lipid Research, vol. 33, no. 5, pp. 727-735, 1992.

[92] M. Bouly, D. Masson, B. Gross, et al., "Induction of the phos-pholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate," Journal of Biological Chemistry, vol. 276, no. 28, pp. 2584125847, 2001.

[93] C. C. van der Hoogt, W. de Haan, M. Westerterp, et al., "Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression," Journal of Lipid Research, vol. 48, no. 8, pp. 1763-1771, 2007.

[94] P. Mardones, A. Pilon, M. Bouly, et al., "Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice," Journal of Biological Chemistry, vol. 278, no. 10, pp. 7884-7890, 2003.

[95] J. N. van der Veen, J. K. Kruit, R. Havinga, et al., "Reduced cholesterol absorption upon PPARS activation coincides with decreased intestinal expression of NPC1L1," Journal of Lipid Research, vol. 46, no. 3, pp. 526-534, 2005.

[96] W. R. Oliver Jr., J. L. Shenk, M. R. Snaith, et al., "A selective peroxisome proliferator-activated receptor S agonist pro-

motes reverse cholesterol transport," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306-5311, 2001.

[97] D. L. Sprecher, C. Massien, G. Pearce, et al., "Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor S agonist," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 359-365, 2007.

[98] T. E. Akiyama, G. Lambert, C. J. Nicol, et al., "Peroxisome proliferator-activated receptor ß/S regulates very low density lipoprotein production and catabolism in mice on a Western diet," Journal of Biological Chemistry, vol. 279, no. 20, pp. 20874-20881,2004.

[99] J. Berger, M. D. Leibowitz, T. W. Doebber, et al., "Novel peroxisome proliferator-activated receptor (PPAR) y and PPARS ligands produce distinct biological effects," Journal ofBiolog-ical Chemistry, vol. 274, no. 10, pp. 6718-6725, 1999.

[100] A.-M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, et al., "Regulation oflipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 9, pp. 1756-1764, 1997.

[101] S. Sunayama, Y. Watanabe, H. Ohmura, et al., "Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance," Atherosclerosis, vol. 146, no. 1,pp. 187-193, 1999.

[102] J. Kobayashi, I. Nagashima, M. Hikita, et al., "Effect of trogli-tazone on plasma lipid metabolism and lipoprotein lipase," British Journal of Clinical Pharmacology, vol. 47, no. 4, pp. 433-439, 1999.

[103] K. Shirai, Y. Itoh, H. Sasaki, et al., "The effect of insulin sen-sitizer, troglitazone, on lipoprotein lipase mass in preheparin serum," Diabetes Research and Clinical Practice, vol. 46, no. 1, pp. 35-41, 1999.

[104] A. Tailleux, G. Torpier, H. Mezdour, J.-C. Fruchart, B. Staels, and C. Fievet, "Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipi-demia and atherosclerosis," Trends in Pharmacological Sciences, vol. 24, no. 10, pp. 530-534, 2003.

[105] J. P. H. van Wijk, E. J. P. de Koning, M. Castro Cabezas, and T. J. Rabelink, "Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes," Diabetes Care, vol. 28, no. 4, pp. 844-849, 2005.

[106] G. D. Tan, B. A. Fielding, J. M. Currie, et al., "The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes," Diabetologia, vol. 48, no. 1, pp. 83-95, 2005.

[107] R. B. Goldberg, "Impact of thiazolidenediones on serum lipoprotein levels," Current Atherosclerosis Reports, vol. 8, no. 5, pp. 397-404, 2006.

[108] K. Nagashima, C. Lopez, D. Donovan, et al., "Effects of the PPARy agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus," Journal of Clinical Investigation, vol. 115, no. 5, pp. 1323-1332, 2005.

[109] I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith, "The effect of pioglitazone on peroxisome proliferator-activated receptor-y target genes related to lipid storage in vivo," Diabetes Care, vol. 27, no. 7, pp. 1660-1667, 2004.

[110] M. Tiikkainen, A.-M. Häkkinen, E. Korsheninnikova, T. Ny-man, S. Mäkimattila, and H. Yki-Jarvinen, "Effects ofrosigli-tazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes," Diabetes, vol. 53, no. 8, pp. 2169-2176, 2004.

[111] M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and Y. Deshaies, "PPAR-y activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion," Diabetes, vol. 52, no. 2, pp. 291-299, 2003.

[112] M. Laplante, W. T. Festuccia, G. Soucy, et al., "Mechanisms of the depot specificity of peroxisome proliferator-activated receptor y action on adipose tissue metabolism," Diabetes, vol. 55, no. 10, pp. 2771-2778, 2006.

[113] H. Kageyama, T. Hirano, K. Okada, et al., "Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-y," Biochemical and Biophysical Research Communications, vol. 305, no. 1, pp. 2227, 2003.

[114] S. Ranganathan and P. A. Kern, "Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes," Journal of Biological Chemistry, vol. 273, no. 40, pp. 26117-26122, 1998.

[115] A. Xu, M. C. Lam, K. W. Chan, et al., "Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6086-6091, 2005.

[116] G. Medina-Gomez, S. L. Gray, L. Yetukuri, et al., "PPAR y 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism," PLoS Genetics, vol. 3, no. 4, p. e64, 2007.

[117] J. R. Jones, C. Barrick, K.-A. Kim, et al., "Deletion of PPARy in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6207-6212, 2005.

[118] A. Gauthier, G. Vassiliou, F. Benoist, and R. McPherson, "Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor y," Journal of Biological Chemistry, vol. 278, no. 14, pp. 11945-11953, 2003.

[119] R. B. Goldberg, D. M. Kendall, M. A. Deeg, et al., "A comparison of lipid and glycemic effects of pioglitazone and rosigli-tazone in patients with type 2 diabetes and dyslipidemia," Diabetes Care, vol. 28, no. 7, pp. 1547-1554, 2005.

[120] S. E. Kahn, S. M. Haffner, M. A. Heise, et al., "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy," The New England Journal of Medicine, vol. 355, no. 23, pp. 2427-2443, 2006.

[121] J. A. Dormandy, B. Charbonnel, D. J. Eckland, et al., "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective piogli-tAzone Clinical Trial in macroVascular Events): a randomised controlled trial," The Lancet, vol. 366, no. 9493, pp. 12791289,2005.

[122] E. Chiquette, G. Ramirez, and R. DeFronzo, "A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors," Archives of Internal Medicine, vol. 164, no. 19, pp. 2097-2104, 2004.

[123] A. Chawla, W. A. Boisvert, C.-H. Lee, et al., "A PPARy-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis," Molecular Cell, vol. 7, no. 1, pp. 161171,2001.

Copyright of PPAb. Research is the property of Hindawi Publishing Corporation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.